Treatment Group
|
N
|
LSM Change From Baseline, mm Hg
|
LSM Difference Compared With Aliskiren/HCTZ (95% CI), mm Hg
|
P
|
| msDBP |
|
|
|
|
| Aliskiren 300 mg/HCTZ 25 mg |
113 |
–11.91±0.74 |
|
|
| Irbesartan 300 mg/HCTZ 25 mg |
117 |
–11.33±0.72 |
–0.57 (–2.58 to 1.43) |
0.576 |
| Amlodipine 10 mg/HCTZ 25 mg |
122 |
–10.30±0.71 |
–1.60 (–3.59 to 0.38) |
0.114 |
| HCTZ 25 mg |
117 |
–7.89±0.73 |
–4.02 (–6.02 to –2.01) |
<0.0001 |
| msSBP |
|
|
|
|
| Aliskiren 300 mg/HCTZ 25 mg |
113 |
–15.79±1.01 |
|
|
| Irbesartan 300 mg/HCTZ 25 mg |
117 |
–15.44±1.00 |
–0.35 (–3.11 to 2.40) |
0.801 |
| Amlodipine 10 mg/HCTZ 25 mg |
122 |
–13.55±0.98 |
–2.24 (–4.97 to 0.49) |
0.107 |
| HCTZ 25 mg |
117 |
–8.62±1.00 |
–7.17 (–9.93 to –4.41) |
<0.0001 |
|
| LSM indicates least-squares mean. Values are shown as least-squares mean±SEM unless otherwise stated. Statistical comparisons were made using an ANCOVA model as described in the Methods. |
